All Stories

  1. Personality domains in early stages of psychosis: a systematic review and meta-analysis
  2. Schizophrenia Genetics Modulates Clinical Depressive Features
  3. Polygenic predisposition to transdiagnostic symptom dimensions and treatment outcomes across psychiatric disorders
  4. The association of diabetes with Alzheimer's disease biomarkers and vascular burden across European aging and memory clinic cohorts
  5. Psychiatric Risk Governance Across Jurisdictions: A Comparative Analysis of Involuntary Treatment, Community Treatment Orders, and Forensic Mental Health Services
  6. Asenapine for aggressive behaviours in psychiatric disorders: a systematic review of efficacy and real-world effectiveness
  7. Factors associated with drug–drug interactions involving citalopram in the UK Biobank
  8. Predicted plasma proteomics from genetic scores and treatment outcomes in major depression: a meta-analysis
  9. Insulin resistance and poorer treatment outcomes in depression: evidence from UK Biobank primary care data
  10. Correction: Mild motor signs and depression: more than just medication side effects?
  11. Mild motor signs and depression: more than just medication side effects?
  12. Local patterns of genetic sharing between neuropsychiatric and insulin resistance-related conditions
  13. Specific symptomatology profile associated with treatment resistant depression: A multicentric study from the Group for the Study of Resistant Depression with a focus on sex
  14. Oropharyngeal microbiota in patients with psychotic disorders: A scoping review on compositional and functional alterations
  15. Predictive coding in neuropsychiatric disorders: A systematic transdiagnostic review
  16. The interface of depression and diabetes: treatment considerations
  17. Shared genetics and causal relationship between sociability and the brain’s default mode network
  18. Polygenic scores and antidepressant treatment outcomes in major depression: a critical integrative review
  19. The gut microbiota's role in bulimia nervosa and binge eating disorder: etiological insights and therapeutic implications from a scoping review
  20. Differences in emotion recognition between nonimmersive versus immersive virtual reality: preliminary findings in schizophrenia and bipolar disorder
  21. The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges
  22. Anhedonia is associated with a specific depression profile and poor antidepressant response
  23. Molecular landscape of the overlap between Alzheimer’s disease and somatic insulin-related diseases
  24. Unravelling the joint genetic architecture between psychiatic and insulin-related traits in the general population
  25. The multivariate genetic architecture of psychiatric and insulin resistance multimorbidity
  26. Genetic factors and symptom dimensions associated with antidepressant treatment outcomes: clues for new potential therapeutic targets?
  27. The clinical perspective on late-onset depression in European real-world treatment settings
  28. Mirtazapine blood levels and antidepressant response
  29. Shared familial risk for type 2 diabetes mellitus and psychiatric disorders: a nationwide multigenerational genetics study
  30. Shared genetics linking sociability with the brain's default mode network.
  31. The association of glucose metabolism measures and diabetes status with Alzheimer’s disease biomarkers of amyloid and tau: A systematic review and meta-analysis
  32. Local patterns of genetic sharing challenge the boundaries between neuropsychiatric and insulin resistance-related conditions
  33. Pharmacological treatments for psychotic depression: a systematic review and network meta-analysis
  34. The bidirectional interaction between antidepressants and the gut microbiota: are there implications for treatment response?
  35. Polygenic scores of subcortical brain volumes as possible modulators of treatment response in depression
  36. Genetic relationship between the immune system and autism
  37. Genetic relationship between the immune system and autism spectrum disorder and traits
  38. 33. SHARED GENETICS LINKING SOCIABILITY WITH THE BRAIN'S DEFAULT MODE NETWORK
  39. T13. EPIGENETIC FACTORS INFLUENCING CO-MORBIDITY OF INSULIN-RELATED SOMATIC AND BRAIN DISORDERS
  40. W12. LOOKING BEYOND LABELS: DEFINING DIMENSIONAL PSYCHIATRIC SYMPTOM CLUSTERS WITH INSULIN-RELATED SOMATIC MEASURES BASED ON LARGE POPULATION-BASED GENETIC DATASETS
  41. W16. THE MULTIVARIATE GENETIC ARCHITECTURE OF PSYCHIATRIC AND SOMATIC INSULIN RESISTANCE-RELATED MULTIMORBIDITY
  42. Correlation between emotion dysregulation and mood symptoms of bipolar disorder: A systematic review and meta‐analysis
  43. Clinical insights into the cross-link between mood disorders and type 2 diabetes: A review of longitudinal studies and Mendelian randomisation analyses
  44. Polygenic scores of subcortical brain volumes as possible modulators of treatment response in depression
  45. Body mass index and clinical outcomes in individuals with major depressive disorder: Findings from the GSRD European Multicenter Database
  46. Real-world characteristics of European patients receiving SNRIs as first-line treatment for major depressive disorder
  47. Clinical specificity profile for novel rapid acting antidepressant drugs
  48. Age or age of onset: which is the best criterion to classify late-life depression?
  49. Clinical correlates and prognostic implications of severe suicidal ideation in major depressive disorder
  50. Hyperthyroidism and depression: a clinical case of atypical thyrotoxicosis manifestation
  51. Melancholic features and typical neurovegetative symptoms of major depressive disorder show specific polygenic patterns
  52. Association between polygenic risk scores of subcortical brain volumes and antidepressant response: a meta-analysis
  53. Emotional side effects of antidepressants: a systematic review
  54. Epigenetic factors influencing the multimorbidity between somatic and brain-insulinopathies
  55. Pharmacological treatment of psychotic depression: a systematic review and network meta-analysis
  56. What emotional regulation strategies are most related to the affective symptoms of bipolar disorder? A systematic review and network meta-analysis
  57. The link between cognition and somatic conditions related to insulin resistance in the UK Biobank study cohort: a systematic review
  58. LOCAL PATTERNS OF SHARED GENETICS AND A GENETIC LATENT FACTOR OF INSULIN RESISTANCE AND NEUROPSYCHIATRIC MULTIMORBIDITY
  59. PSYCHIATRIC AND INSULIN-RELATED SOMATIC MULTIMORBIDITY: INSIGHTS INTO UNDERLYING GENETIC ARCHITECTURE AND BRAIN STRUCTURES INVOLVED
  60. T75. NO LABELS NEEDED: UNDERSTANDING PSYCHIATRIC DISORDERS BASED ON GENETIC TRAITS
  61. Patterns of antipsychotic prescription and accelerometer-based physical activity levels in people with schizophrenia spectrum disorders: a multicenter, prospective study
  62. Insulinopathies of the brain? Genetic overlap between somatic insulin-related and neuropsychiatric disorders
  63. The sociodemographic and clinical phenotype of European patients with major depressive disorder undergoing first-line antidepressant treatment with NaSSAs
  64. Temporally ordered associations between type 2 diabetes and brain disorders – a Danish register-based cohort study
  65. The Italian version of the Brief Assessment of Cognition in Affective Disorders: performance of patients with bipolar disorder and healthy controls
  66. Epigenetics and aetiology of mental illness
  67. Clinical correlates and prognostic impact of binge-eating symptoms in major depressive disorder
  68. The dilemma of polypharmacy in psychosis: is it worth combining partial and full dopamine modulation?
  69. Machine Learning Prediction of Comorbid Substance Use Disorders among People with Bipolar Disorder
  70. Depression, antidepressants, and insulin resistance: which link?
  71. The U-shaped relationship between parental age and the risk of bipolar disorder in the offspring: A systematic review and meta-analysis
  72. Epigenetic Basis of Psychiatric Disorders: A Narrative Review
  73. Evidence on sociodemographic and clinical correlates of antidepressant combination or augmentation with second-generation antipsychotics in major depressive disorder
  74. Polygenic risk scores for neuropsychiatric, inflammatory, and cardio‐metabolic traits highlight possible genetic overlap with suicide attempt and treatment‐emergent suicidal ideation
  75. Obsessive-compulsive symptoms in major depressive disorder correlate with clinical severity and mixed features
  76. Insulinopathies of the brain? Genetic overlap between somatic insulin-related and neuropsychiatric disorders
  77. A meta-analysis of polygenic risk scores for mood disorders, neuroticism, and schizophrenia in antidepressant response
  78. The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries
  79. Bipolar disorder and comorbid substance use disorder: a machine-learning approach
  80. Genetic dissection of the clinical heterogeneity of major depressive disorder
  81. Hyperthyroidism and depression: a clinical case of atypical thyrotoxicosis manifestation
  82. Hyperthyroidism and depression: focusing on this complex interplay
  83. The Italian Version of the Brief Assessment of Cognition in Affective Disorders: Performance of Patients with Bipolar Disorder and Healthy Controls
  84. The U-shaped relationship between parental age and the risk of bipolar disorder in the offspring – A systematic review and meta-analysis
  85. The cross-link between major depressive disorder and type 2 diabetes mellitus: a review of longitudinal and mendelian randomisation studies
  86. Social withdrawal as a trans-diagnostic predictor of short-term remission: a meta-analysis of five clinical cohorts
  87. P.0882 A meta-analysis of polygenic risk scores for mood disorders, neuroticism, and schizophrenia in antidepressant response
  88. W68. A META-ANALYSIS OF POLYGENIC RISK SCORES FOR MOOD DISORDERS, NEUROTICISM, AND SCHIZOPHRENIA IN ANTIDEPRESSANT RESPONSE
  89. TH59. INSULINOPATHIES OF THE BRAIN? GENETIC OVERLAP BETWEEN SOMATIC INSULIN-RELATED AND NEUROPSYCHIATRIC DISORDERS
  90. Gastrointestinal side effects associated with antidepressant treatments in patients with major depressive disorder: A systematic review and meta-analysis
  91. A meta-analysis of polygenic risk scores for mood disorders, neuroticism, and schizophrenia in antidepressant response
  92. Higher polygenic risk scores for schizophrenia may be suggestive of treatment non-response in major depressive disorder
  93. Insulinopathies of the brain? Genetic overlap between somatic insulin-related and neuropsychiatric disorders
  94. Polygenic risk scores for psychiatric, inflammatory, and cardio-metabolic traits and diseases highlight possible genetic overlaps with suicide attempt and treatment-emergent suicidal ideation
  95. P.169 Genetic overlap between somatic insulin-related and neuro-psychiatric disorders
  96. P.171 Higher polygenic risk scores for schizophrenia may be suggestive of treatment non-response in major depressive disorder
  97. P.179 Polygenic risk scores for multiple psychiatric, inflammatory and cardio-metabolic traits highlight possible genetic overlap with suicide attempt
  98. Higher polygenic risk scores for schizophrenia may be suggestive of treatment non-response in major depressive disorder
  99. Reduced plasma Fetuin-A is a promising biomarker of depression in the elderly
  100. P.306 Reduced chemokine ligand 1/GRO chemokine plasma levels are a possible biomarker of elderly depression
  101. M74 HIGHER POLYGENIC RISK SCORES FOR SCHIZOPHRENIA MAY BE SUGGESTIVE OF NON-RESPONSE TO DRUGS FOR DEPRESSION IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER
  102. Reduced CXCL1/GRO chemokine plasma levels are a possible biomarker of elderly depression
  103. P.4.01 C-X-C chemokine signalling is implicated in major depressive disorder in a sample of Korean elderly subjects
  104. SA92THE INFLUENCE OF THE SEROTONIN TRANSPORTER GENE 5-HTTLPR POLYMORPHISM ON SUICIDAL BEHAVIORS: A META-ANALYSIS
  105. The influence of the serotonin transporter gene 5-HTTLPR polymorphism on suicidal behavior: a meta-analysis
  106. The influence of the serotonin transporter gene 5-HTTLPR polymorphism on suicidal behaviors: a meta-analysis
  107. A Polygenic Risk Score of glutamatergic SNPs associated with schizophrenia predicts attentional behavior and related brain activity in healthy humans